Apixaban for the Acute Treatment of Venous Thromboembolism in Children
A Randomized, Open-Label, Active Controlled, Safety and Descriptive Efficacy Study in Pediatric Subjects Requiring Anticoagulation for the Treatment of a Venous Thromboembolic Event
-
Clinical Trial Information
Trial Contact: Spinelli, Jennifer
Trial Phone: 321.841.5357
-
IRB No: 19.014.01
Protocol Abbrev: B0661037
Principal Investigator: Shveta Gupta, MD
Phase: Drug: Phase IV
Age Group: Pediatric
Secondary Protocol No: B0661037
Treatment: Drug: Apixaban Drug: Standard of Care
Therapies Involved: Medication
ClinicalTrials.gov ID: NCT02464969
-
Objective
- Primary: To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
- Secondary: To evaluate apixaban PK and anti-FXa activity in pediatric subjects requiring anticoagulation for the treatment of a VTE. -
Key Eligibility
1. 28 days to <18 years of age with a minimum weight of 4 kg at the time of randomization.
2. Presence of an index VTE which is confirmed by imaging.
3. Intention to manage the index VTE with anticoagulation treatment for at least 6 to 12 weeks.
